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Current Status of Stem Cell 
Therapy for Sepsis and Acute 
Respiratory Distress Syndrome
Raquel Guillamat-Prats and Antonio Artigas
Abstract
Sepsis and acute respiratory distress syndrome (ARDS) are life-threatening 
diseases with high mortality, around 40%, and morbidity in all the critical care 
units around the world. After decades of research, and numerous pre-clinical and 
clinical trials, sepsis and ARDS remain without a specific and effective pharmaco-
therapy and essentially the management remains supportive. Over the last years, 
cell therapies gained potential as a therapeutic treatment for ARDS and sepsis. 
Based on numerous pre-clinical studies, there is a growing evidence of the potential 
benefits of cell-based therapies for the treatment of sepsis and ARDS. Different cell 
subtypes have been used for the treatment of both syndromes; however, the major 
part of the studies is using mesenchymal stem/stromal cells (MSC). Also, other 
relevant groups performed some pre-clinical studies using induced pluripotent 
stem cells (iPSC) for the treatment of both syndromes and alveolar type II cells for 
ARDS treatment. Numerous questions need further study, including determin-
ing the best source for the progenitor cells isolation, their large-scale production, 
and cryopreservation. Also, the heterogeneity of patients with sepsis and ARDS is 
massive, and the stratification of the patients will help us to determine better the 
therapeutic effect of these cell therapies. In this review, we are going to describe 
briefly the different cell types, their potential sources, and characteristics and 
mechanism of action. We will review several pre-clinical and clinical studies in 
ARDS and sepsis.
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1. Introduction
Sepsis and acute respiratory distress syndrome (ARDS) are life-threatening 
diseases with high mortality and morbidity in all the critical care units around the 
world [1–4]. Severe sepsis is a complex syndrome produced by the response to a 
systemic infection. The infection produces a general inflammatory response, such 
as tachycardia, elevated white cell count and systemic release of pro-inflammatory 
cytokines, and this can lead to an acute organ dysfunction. Sepsis is producing more 
than 5 million deaths per year worldwide [5–8].
The lung is one of the most affected organs during sepsis, and for that reason, 
one of the main indirect causes of ARDS is sepsis. ARDS can also be produced 
by a direct injury as a pulmonary infection or a trauma. ARDS is a multifactorial 
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syndrome characterized by increased lung permeability, hypoxemia, the absence of 
cardiogenic pulmonary edema, the disruption of the alveolar-capillary barrier, and 
widespread inflammation. Every year between 1.5 and 4.5 cases per 100,000 inhab-
itants/year in Europe is detected and in the United States approximately 200,000 
new cases are identified per year [1, 5, 8].
There is no definitive therapy that targets the underlying pathobiology of sepsis 
exists. Nowadays, the treatment is based on antibiotics, infection source control, 
fluid resuscitation, and organ support [9, 10]. Moreover, several patients die due 
to secondary infections during the year after the hospital discharge. After decades 
of research, and numerous pre-clinical and clinical trials, sepsis and ARDS remain 
without a specific and effective pharmacotherapy and essentially the management 
remains supportive. Nowadays, patients with ARDS have been treated with several 
ventilator interventions such as lower tidal volumes, higher positive end-expiratory 
pressure (PEEP), and adjuncts such as prone positioning, neuromuscular blockade, 
and extracorporeal membrane oxygenation [11–14].
Current advances in the study and knowledge of stem cells have permitted to 
start using them as a novel treatment for ARDS and sepsis. Based on numerous 
pre-clinical studies, there is a growing evidence of the potential benefits of cell-
based therapies for the treatment of sepsis and ARDS. Several cell types are used 
in the last years for the treatment of both syndromes showing high efficiency 
[15, 16].
In animal models, cell therapies have demonstrated noteworthy therapeutic 
properties including the modulation of the immune system, the release of several 
factors with growth factor, and antibiotic and anti-inflammatory properties. Cell 
therapies were tested in several animal models, such as mouse, rat, sheep, and pig 
models, using several septic and ARDS models. Moreover, different cell types and 
different administration pathways (intravenously, intraperitoneal, or local adminis-
tration into the lung) were used as a treatment.
Furthermore, in the last years, a couple of clinical studies started using cell 
therapies for the treatment of sepsis and ARDS, and some safety and efficient 
results are published.
This chapter summarizes the different progenitor cells that can be used as a 
therapy, the mechanisms of action, and the results in pre-clinical and clinical stud-
ies in ARDS and in sepsis and future directions.
2. Cell sources for transplantation
We define cell therapy as a therapeutic product containing cells, which usu-
ally is administered into the patients to replace or repair damaged tissues or cells. 
Nowadays, several diseases are treated with cell therapies, for example, bone mar-
row transplants for the treatment of some specific cancers.
In the last years, several researchers and physicians are working to convert some 
cell therapies from potential treatments to real therapies. There is an effort to detect 
the factors that the cells are secreting and have this beneficial effect and also to 
set up the safety and efficacy. Additionally, these therapies are really expensive, 
and there are several problems associated such as the difficulty to obtain, expand, 
purify, and manipulate these cells. So, we also have to work on the cost-effective 
options.
Cell therapies have shown their potential in biomedicine, and their utility for 
several indications has been demonstrated and this utility will expand in the future. 
Nevertheless, progressing cell therapies from bench to bedside takes decades of 
hard and slow work.
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Several pharmaceutical companies hold a number of stem cell lines and work 
to advance in cell therapies. Finding new culture mediums that able to maintain or 
differentiate into the desired cell type with high throughput and also diminish the 
risk of causing cancer is quite difficult. Afterwards, the laboratories and the com-
panies will need to implement several protocols to work under good manufacturing 
practice guidelines (GMP) and follow specific storage rules of products that want to 
be used as a therapy. Several delicate conditions need to be fulfilled for these cells, 
to be approved by health authorities, and to be used in humans and in clinical trials.
First, we want to review the different cell types, their potential sources, and 
characteristics and underlie why mainly mesenchymal stem/stromal cells are used 
for the treatment of sepsis and ARDS. Some pre-clinical studies using induced 
pluripotent stem cells (iPSC) for the treatment of both syndromes and alveolar type 
II cells for ARDS treatment also presented some interesting results. The different 
cell subsets are summarized in Table 1.
2.1 Embryonic stem cells (ESCs)
ESCs are pluripotent cells derived from the inner blastocyst cell mass and con-
stitute a potentially unlimited source of cells that could be differentiated into any 
progenitor cell and used in the clinical trials. ESCs have high plasticity and theoreti-
cally unlimited capacity for self-renewal; ESCs have been suggested for regenerative 
medicine and tissue replacement; however, their embryologic origin is linked to 
significant ethical issues regarding the use of these cells [17–19].
2.2 Induced pluripotent stem cells (iPSC)
A new type of pluripotent cells, iPSCs, can be obtained by reprogramming 
animal and human somatic (differentiated) cells. Usually, iPSCs are obtained from 
dermal fibroblasts because it is an easy source and did not produce any damage to 
the donor when we obtain them. The cells should be dedifferentiated following 
Cell 
type
Harvest 
method
Advantages Disadvantages Benefits in ARDS Benefits in sepsis
ESC Embryos Totipotent High tumorigenic 
potential.
Ethical problem
Easy to differentiate to 
AEC2. No tested in vivo
Reduces mortality 
and decreases lung 
inflammation
iPSC Skin 
biopsy
Easy isolation
No rejection
High tumorigenic 
potential
Easy to differentiate to 
AEC2. No tested in vivo
—
MSC Bone 
marrow 
or adipose 
tissue
Easy isolation
No rejection
High tumorigenic 
potential
Immunomodulatory 
effect. Reduces 
inflammation and lung 
edema
Reduces mortality 
and inflammation. 
Antibacterial activity 
and antiapoptotic 
activity
EnPC Blood Nontumorigenic Difficult isolation and 
small amount
Maintains the integrity of 
the lung and improves the 
lung function
Reduces the 
sepsis damage 
re-establishing micro 
and macrocirculation
EpPC Donor 
tissue
Nontumorigenic Difficult isolation and 
small amount
AEC2 cells were 
tested improving lung 
function and reducing 
inflammation
—
Table 1. 
Summary of the cell sources and their benefits.
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reprogramming and finally are able to express four transcription factors such as 
Ocet3/4, Sox2, Klf-4, and c-Myc. They grow indefinitely and differentiate into 
all cell types of the human body, and also they can be obtained in autologous way 
reducing the graft-versus-host disease [20–22].
The main problem is that the dedifferentiation and reprogramming have low 
efficiency, and their genomic modification could create associated problems that 
until now are unknown or have not been studied and have a high tumorigenicity risk 
[23–25]. The potential applications of iPSCs in sepsis and ARDS are many [26, 27].
2.3 Endothelial progenitor cells (EnPC)
The endothelial damage is one of the main hallmarks of ARDS, and EnPCs have 
the ability to regenerate endothelial cells and could have an unlimited role in repair-
ing the damaged endothelium. EnPCs have been defined as circulating cells that 
have ability to adhere to the endothelium at sites of hypoxia and ischemia secreting 
pro-angiogenic factors and generate a new vessel [28].
EnPCs express hematopoietic surface cell markers such as CD34. However, the 
role, isolation, and identification of these cells are not completely elucidated.
EnPCs can be useful as a regenerative instrument to treat several vascular dis-
eases, but the ability to adhere to the endothelium at sites of hypoxia and ischemia 
secretes pro-angiogenic factors and generates a new vessel [29, 30].
Very few pre-clinical studies have been published, which have used EnPCs in 
sepsis and ARDS [31–34].
2.4 Epithelial progenitor cells (EpPC)
Some epithelial progenitors of the lung alveolar compartment have also been 
identified, but their isolation is really difficult and the number of cells that could be 
obtained is really low. EpPCs might be useful in the treatment of ARDS.
EpPCs are specified during development in each tissue and are highly regu-
lated by epithelial-mesenchymal interactions. Different tissues have different 
EpPCs with small adjustments in their function; however, their maintenance, 
activation, and differentiation are regulated by the same pathways between all 
the tissues [35, 36].
The use of alveolar-epithelial type II cells (AE2C) for the treatment of ARDS 
has been demonstrated; these cells are more differentiated than EpPCs, but still can 
proliferate and differentiate into alveolar-epithelial type I cell, that are the complete 
differentiated cells in the lung epithelia. AE2C cells can only be isolated from the 
lungs of organ donors and may have problems in graft-versus-host disease [37–39]. 
The isolation of AE2C is laborious, but they have less ethical problems and tumori-
genicity potential.
2.5 Mesenchymal stem cells (MSC)
MSCs are the best described cells and mostly used as a cell therapy. MSCs are 
multipotent cells that have been isolated from several tissues such as umbilical cord 
blood, placenta, adipose tissue, lung, and bone marrow.
The International Society of Cellular Therapy defined that MSCs should follow 
the three criteria: (1) MSCs must be adherent to plastic; (2) MSCs must express 
some cell surface markers, such as CD105, CD90, and CD73, but must not express 
other markers, including CD45, CD34, CD14, or CD11b; and (3) MSCs must have 
the capacity to differentiate into mesenchymal lineages (osteoblasts, adipocytes, 
and chondroblasts) in in vitro conditions [40].
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MSCs have a high degree of plasticity and can be differentiated into a variety 
of cell lineages, but they do not possess the complete plasticity of ESCs. However, 
MSCs have some advantages because of their easy isolation and enormous propaga-
tion in culture and also because their use does not involve the ethical problems 
associated to the use of ESCs [41]. Moreover, they can be obtained in autologous 
way diminishing the immune rejection problem. In addition, MSCs are not immu-
nogenic; they have an innate ability to avoid detection by a recipient’s immune 
system because they express intermediate levels of major histocompatibility class I 
but do not express major histocompatibility class II [42–44].
Several experimental studies have indicated that MSCs may have potential thera-
peutic application in sepsis and ARDS [45–49]. It has also been reported that MSCs 
release several microvesicles that might have the therapeutic potential [50, 51].
3.  Mesenchymal stem cell therapy for sepsis and acute respiratory 
distress syndrome
The complex pathophysiology of sepsis and also of ARDS requires a therapy 
with a wide range of properties. The heterogeneity of the host response in front of 
sepsis or ARDS makes it difficult to find a proper drug that works as a therapy. Stem 
cells are potential therapeutic agents with a diverse spectrum of action and can 
act at different levels of the pathophysiology of ARDS or sepsis, non only treating 
inflammation, moreover affecting coagulation, enhancing antimicrobial effect, 
modulating the innate and adaptive immune response, and reducing endothelium 
permeability and edema.
MSCs can be administered intravenously, but then only a small percentage of 
injected cells arrive to the injury site. Usually, MSCs get trapped into the lung’s 
microvasculature, and after some hours, they are engulfed by macrophages and they 
disappear. It is well known that cells do not engraft into the tissue and their primary 
action mechanism is the secretion of soluble factors with therapeutic properties.
MSCs release into the extracellular media bioactive cytokines, chemokines, 
angiogenic factors, and/or growth factors. Moreover, it has been described that MSCs 
also release extracellular vesicles with bioactive compounds. Extracellular vesicles 
are small vesicles made by a phospholipid bilayer and encapsulate proteins, lipids, or 
miRNAs or other compounds that are protected from the media and can be phago-
cytosed by other cells and act on them. Nowadays, the use of extracellular vesicles to 
target specific cells is also a raising up therapy competing with cell therapies; how-
ever, there is still a lot to define about the secretome of the MSC to be able to mimic its 
therapeutic effects.
All these factors directly secreted to the media or inside extracellular vesicles 
regulate intracellular pathways from different cells and can act on the innate and 
adaptive immune system. The different effects or mechanisms are described in the 
following sections and in Figure 1.
3.1 Effects on the innate immune system
Inflammation is one of the main drivers of ARDS and sepsis pathogenesis. 
During ARDS, the injury of the lung endothelium and epithelium is producing 
a recruitment of pro-inflammatory cells such as neutrophils and monocytes into 
the alveolar space. These pro-inflammatory cells release several pro-inflammatory 
cytokines, for example, TNF-α, IL-1β, and IL-6 [52–54]. Moreover, neutrophils 
are secreting several ROS enhancing the damage of the endothelium and epithelial 
layers propagating the damage [55–57].
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During sepsis, the infection activates TLR4, which leads to the activation of 
MyD88 and NF-kb and the transcription of pro-inflammatory cytokines such as 
TNF-α, IL-1β, and IL-6. After the first hours following the infection, there is a 
specific storm of cytokines [58].
MSCs have the ability to modulate the immune response and secrete several 
anti-inflammatory cytokines such as IL-4, IL-10, or IL-13 [59]. Furthermore, they 
regulate inflammation using different strategies and acting on different cells, which 
are described in the following sections.
3.1.1 Effects on humoral immune response
Numerous studies proved that MSCs decrease the pro-inflammatory cytokine 
response (TNF-α, IFN-γ, and IL-1α, -1β, -6, -12, and -17). They promote this effect 
while increasing concentrations of the anti-inflammatory agents, including IL-1 
receptor antagonist (IL-1Ra), IL-10, tumor necrosis factor-inducible gene 6 protein 
(TSG-6), cyclooxygenase-2 (COX-2), insulin-like growth factor 1 (IGF-1), and 
prostaglandin-E2 (PGE2) [60, 61].
All these factors act on different cells; for example, IL-1Ra is able to reduce 
the production of inflammatory TNF-α in macrophages and also inhibits helper-T 
lymphocytes activation. TSG-6 has a potent anti-inflammatory effect acting in 
macrophages and polarizing them from a pro- to an anti-inflammatory phenotype 
while reducing the secretion of inflammatory chemokines by these cells. IGF-1 
has been described as an anti-apoptotic compound, and during sepsis and ARDS, 
less apoptosis of the endothelium and epithelium cells reduces the damage and the 
associated inflammation [62, 63].
3.1.2 Effects on the inflammasome
The inflammasome is a multiprotein intracellular oligomer that detects patho-
genic microorganisms and other factors and activates an inflammatory response. 
Inflammasome activates caspase-1 and caspase-1 cleaves the precursor cytokines 
Figure 1. 
Potential mechanisms of the cell therapies.
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pro-IL-1β and pro-IL-18, generating the biologically active cytokines IL-1β and IL-18, 
respectively. Caspase 1 also activates following compounds derived from the host innate 
immune system that can lead to pyropotosis (an inflammatory form of cell death) [64].
Generally, myeloid cells such as neutrophils, monocytes, and macrophages are 
expressing inflammasome proteins such as pattern-recognition receptors (PRRs), 
toll-like receptors (TLR), or C-type lectin receptors in their membrane. NLRP3 is the 
best characterized and versatile inflammasome and is mainly expressed by myeloid 
lineage cells and stimulated by the activation of TLR and other signals [64, 65].
MSCs can regulate the NLRP3 inflammasome activation through the secretion of 
PGE2 that leads to an increase in IL-10 production by macrophages. The decrease in 
NLRP3 activation moderates cell death and organ dysfunction [65].
3.1.3 Effects on neutrophil response
Sepsis is associated with neutropenia, and it has been shown that MSCs are able 
to increase the neutrophil counts after their administration [66, 67]. The activity 
and survival of neutrophils were also increased in the lung during ARDS; this effect 
is produced through the stimulation of TLR-3 by MSCs.
During sepsis and ARDS, the injury or pathogen activates some recognition recep-
tors that promote activated neutrophils recruitment. Neutrophils release some antimi-
crobial compounds and produce some traps to eliminate the pathogen. During sepsis, 
the general infection produces an overactivation of the neutrophils that migrate to 
inflamed and noninflamed tissue and can lead to an organ dysfunction [68].
Several pre-clinical studies have demonstrated that MSCs are able to modify neu-
trophils behavior, maintaining their bactericidal function but reducing the host injury.
In pre-clinical sepsis models, MSC therapy diminishes neutrophil infiltration 
into several organs such as lung, liver, gut, and kidney, reducing injury and improv-
ing organ function. Besides, MSCs augment neutrophil-mediated phagocytosis, 
improving the clearance of bacteria. It has been demonstrated that the protective 
effect of MSCs in systemic sepsis is clearly mediated by neutrophils, because their 
depletion abolishes the protective effect of MSCs [55, 69, 70].
3.1.4 Effects on monocyte/macrophage response
Monocytes and macrophages are present in practically all tissues. They have a 
wide range of functions like maintenance of the tissue homeostasis, immunologic 
functions, and participation in several metabolic pathways [71, 72].
It is well known that, in the course of sepsis and ARDS, macrophages get 
dysfunction and are not able to perform their activity as usual. Several groups focus 
in the use of MSCs as modulator of macrophages activity [73, 74]. Tissue resident 
macrophages and also circulating monocytes that migrate into the tissue and 
convert to macrophages can polarize to different phenotypes. Pro-inflammatory or 
M1 macrophages produce several pro-inflammatory cytokines and are involved in 
the elimination of pathogens. Anti-inflammatory/reparative or M2 macrophages 
secrete more anti-inflammatory compounds and are involved in the clearance of 
apoptotic cells. Alteration of M1 macrophages to a M2 phenotype has been demon-
strated to be important to damage resolution.
MSCs have the ability to secrete several factors that polarize macrophages to 
a M2 phenotype, promoting a resolution phase, increasing phagocytic activity, 
and decreasing inflammation. It has been described that macrophages secrete 
PGE-2 that is able to increase the production of IL-10, SOCS-3, TGF-β, TSG-6, 
and others [60, 75]. All these factors are able to reduce the recruitment/migration 
of pro-inflammatory cells into the tissue, preventing organ dysfunction and also 
Innovations in Cell Research and Therapy
8
decreasing the production of pro-inflammatory cytokines such as TNF-α or IFN-γ 
by macrophages [76].
Furthermore, complement activation pathway is also upregulated by MSCs infu-
sion, what leads to a more efficient clearance of pathogens. MSCs, as we had previ-
ously described, secrete KGF that also promotes a M2 phenotype and can transfer 
mitochondria to macrophages, also reducing their pro-inflammatory phenotype  
[73, 77]. During ARDS, it has been shown that MSCs attenuate the damage induced by 
bacteria or LPS through the inhibition of Wnt/β-catenin pathway. The effects of MSCs 
on the macrophage activation varies quite a lot depending on the organ, the stage of 
the disease, and the steady-state of these macrophages when MSCs are infused.
3.2 Effects on adaptive immune response
In several diseases, there is an enhanced activation and proliferation of T and B 
cells, and this is also happening during sepsis. MSCs have the ability to diminish this 
cell activity and their proliferation [78, 79].
Explicitly, it has been shown that MSCs inhibit effector T-cell activation and 
can increase regulatory T-cell numbers, while suppressing propagation of CD4+ 
T-helper cells, CD8+ cytotoxic T lymphocytes, and natural killer cells [80, 81]. 
This effect is mediated through the secretion of PGE-2 and TGF-β1 [82]. Moreover, 
MSCs promote the formation of CD8+ regulatory T cells that might decrease 
cytotoxicity caused by cytotoxic lymphocytes [83, 84].
Regulatory T cells are a subclass of T cells, which functions in modulating the 
immune system and maintaining the antigen tolerance. These cells are able to limit 
inflammation and reduce organ dysfunction in sepsis, and MSCs have the capacity 
to regulate regulatory-T cell function [81, 85]. It has been verified that regulatory T 
cells subset is necessary to eliminate bacteria during infections.
MSCs induce regulatory T cells promoting their efficiency and enhancing sepsis 
or ARDS resolution [86, 87].
It has also been reported that MSCs modified the activity of other cells from the 
adaptive immune system such as NK, regulatory B cells, and dendritic cells.
3.3 Antibiotic properties
MSCs have been reported to have antibiotic/antimicrobial effects. They reduced 
bacterial levels in bronchoalveolar lavage, blood, spleen, and lung tissue. Generally, 
the antimicrobial effect of MSCs is due to their effect on host immune cells. MSCs 
have the ability to increase the phagocytic capacity of the host immune cells such as 
macrophages, monocytes, dendritic cells, and neutrophils [54, 73, 88]. It has been 
shown that this effect is produced through the production of keratinocyte growth 
factor (KGF) or also named fibroblast growth factor 7 (FGF7) [62, 69, 89].
Besides, MSCs are producing other factors with antibiotic properties per se. For 
example, in some pre-clinical models, it has been described that mouse MSCs secrete 
lipocalin-2, also known as neutrophil gelatinase-associated lipocalin (NGAL), which 
limits bacterial growth by iron sequestration. Human MSCs secrete LL-37, also known 
as cathelicidin antimicrobial peptide 18, described as antimicrobial peptide [90]. 
Patients with a high level of LL-37 were more likely to survive to a strong infection.
3.4 Antiapoptotic effects
During sepsis and ARDS, the apoptosis of endothelial, epithelial, and immune 
cells is one of the main descriptors of the severity of the disease. MSC therapy has 
been confirmed that it is able to limit the apoptosis of host cells.
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The antiapoptotic capacity has been tested in vitro incubating neutrophils with 
MSCs or their supernatants and also in vivo where resident macrophages have 
presented less apoptosis [91, 92]. It seems that antiapoptotic effect of MSCs does 
not require cell-cell contact, and IL-6 and FGF7 have been described as the main 
drivers of this effect.
The role of MSCs in the decrease of monocytes, macrophages, and neutrophils 
apoptosis is directly associated with an increase in the clearance of bacteria and also 
can explain the antibiotic properties of MSCs [69].
3.5 Regulation of permeability
The endothelial and epithelial injury is a crucial characteristic of sepsis and 
ARDS. Throughout sepsis and ARDS, the barrier function of the endothelium and 
epithelium is destroyed due to the loss of their integrity and the disruption of the 
junction proteins between cells [1, 93].
MSCs have been described that they are able to decrease permeability and 
decrease the disturbance of the membrane, promoting the production of tight junc-
tion proteins and limiting the binding of inflammatory cells to the endothelium. It 
seems from some in vitro studies that the preserving effect of MSCs on permeability 
is due to the secretion of IL-1Ra and PGE-2, which decrease inflammation and 
reduce endothelial and epithelial cell apoptosis [94–96].
4. Mechanisms by which MSCs exert their effects
MSCs work by multiple mechanisms and can exert their effect through cell-cell 
contact, secreting several factors directly to the media or through the release of 
extracellular vesicles.
It seems that during sepsis and ARDS the MSC are not really engrafted in 
any tissue; however, it has been demonstrated that cells migrate to the site of the 
injury and they are retained there for a while. It has been shown that some effects 
are produced through cell-cell contact between MSCs and alveolar epithelial cells 
mainly to regulate endothelial integrity creating some junctions and transferring 
mitochondria or other cellular products with therapeutic effect [58, 60, 89].
In the last sections, we reviewed the effects of MSCs through the secretion of 
several factors such as antimicrobial peptides, antiapoptotic effectors, or immuno-
modulatory mediators.
Besides, MSCs release extracellular vesicles, which encapsulate several cel-
lular components, including mitochondria and gene products such as miRNAs 
and mRNAs. Moreover, it has been described that some extracellular vesicles can 
also encapsulate lipids and proteins. Several studies have described the delivery 
of miR-223 that is transfer to macrophages and cardiomyocytes and reduces their 
inflammatory response. Also, the mRNA from KGF has also been detected inside 
these extracellular vesicles, producing its effect in the endothelium and epithelium 
and enhancing their repair [97–99].
5. Clinical trials
The encouraging preclinical data suggest that cell-based therapies capable of 
simultaneously affecting multiple processes constitute a promising new approach 
to sepsis and ARDS treatment [100]. MSCs can be efficiently cultured from bone 
marrow, umbilical cord blood, adipose tissue, and other sources and have a low 
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Study title Register number Sepsis/
ARDS
Cell type Phase Dose and via Start date Finish date Country Reference
Adipose-derived mesenchymal stem cells in acute 
respiratory distress syndrome
NCT01902082 ARDS MSC Phase 1 1 × 106 intravenous November 
2012
November 
2014
China [104]
Russian clinical trial of mesenchymal cells in patients with 
septic shock and severe neutropenia
NCT01849237 Sepsis MSC Phase 1/2 1–2 millions/kg/day 
intravenous
December 2012 May 2015 Russia [109]
Human mesenchymal stem cells for acute respiratory 
distress syndrome (START)
NCT01775774
NCT02097641
ARDS MSC Phase 1/2a 1 or 5 or 10 million 
cells/kg
July 2013 February 2018 USA [102, 108]
Cellular immunotherapy for septic shock: a phase I trial 
(CISS)
NCT02421484 Sepsis MSC Phase 1 0.3 or 1 or 3 million 
cells/kg
May 2015 June 2017 Canada [103]
Treatment of severe acute respiratory distress syndrome 
with allogeneic bone marrow-derived mesenchymal 
stromal cells
NCT02215811 ARDS MSC Phase 1 Not known. Cells 
are combined with 
ECMO
March 2014 December 2015 Sweden
Human umbilical cord-derived mesenchymal stem cell 
therapy in acute lung injury (UCMSC-ALI)
NCT02444455 ARDS MSC Phase 1/2 5 × 105/kg intravenous May 2015 December 2017 China
A phase 1/2 study to assess MultiStem® therapy in acute 
respiratory distress syndrome (MUST-ARDS)
NCT02611609 ARDS Multistem
(MSC)
Phase 1/2 Not known January 2016 November 
2018
USA/UK
Effects of administration of mesenchymal stem cells on 
organ failure during the septic shock (CSM choc)
NCT02883803 Sepsis MSC Phase 1 106/kg intravenous December 2016 December 2019 France
Mesenchymal stem cells (MSCs) for treatment of 
acute respiratory distress syndrome (ARD) in stem cell 
transplant patients
NCT02804945 ARDS MSC Phase 2 3 × 106 cell/kg 
intravenous
February 2017 February 2019 USA
Repair of acute respiratory distress syndrome by stromal 
cell administration (REALIST)
NCT03042143 ARDS MSC Phase 1/2 2 doses, not specified September 
2017
September 
2020
UK
Table 2. 
Phase 1 and phase 2 clinical studies with cell therapies for ARDS and sepsis (adapted from reference X).
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expression of major histocompatibility antigens, permitting allogeneic therapy 
without need for immunosuppression, and no safety issues have been identified in 
hundreds of patients [101].
Two recent phase 1 dose-escalation safety of MSCs in patients with ARDS 
[102] and septic shock [103] raised no safety concerns adding a growing body of 
evidence that MSCs can be safety administered intravenously at several millions 
cells per kilogram to critically ill patients. Zheng et al. assigned 12 patients with 
moderate-to-severe ARDS to receive 1 million adipose-derived MSCs/kg or saline, 
reporting no adverse infusion-related events [104]. Nevertheless, the intravenous 
administration of high doses of MSCs may be associated with vascular thrombosis. 
Recently published trials of MSCs in ARDS and in sepsis and studies in progress are 
summarized in Table 2.
Larger phase 2 and phase 3 trials are required to define the adverse events related 
to cell therapy. These future studies should be designed considering the use of fresh 
versus cryopreserved cell product, the optimal dosing and route administration reg-
imen, and which biologic and clinical outcomes should be assessed for insights into 
safety and efficacy. Central challenges in ensuring consistency in final product in 
the cell therapy field are the lack of consensus for in vitro potency assays to optimize 
donor selection, MSC tissue source, and optimal MSC culture condition. Without 
an accepted potency assay, the lack of a signal of biological effect in patients is 
difficult to interpret. One approach may be to measure paracrine factors such as 
angiopoietin-1 and KGF. Phase 2 trials should identify which biological markers are 
altered by cell-based therapy. However, the optimal approach for patient selec-
tion in sepsis and ARDS trials remains a challenge. ARDS and sepsis are clinical 
syndromes rather than a disease, with a lack of specificity of clinical criteria. 
Thirty-five percent of patients with ARDS have a hyperinflammatory phenotype, 
associated with a higher mortality and a different therapeutic response. Patients 
with a hyperinflammatory phenotype might be better candidates for therapy with 
MSCs [105, 106].
There is a growing evidence for the therapeutic effects of extracellular vesicles 
from MSCs, raising the possibility that cell-free therapy consisting of exosomes 
or microvesicles or MSC culture media might be produced and could be tested in 
patients with sepsis, ARDS, acute kidney injury, or traumatic brain injury. Several 
steps would be needed for this approach to become a reality, including optimiza-
tion of purification methods for isolation of the required fractions of extracellular 
vesicles from MSCs accompanied by a comprehensive characterization of RNA, 
microRNA, lipids, and proteins in exosomes or microvesicles [50].
Although cell donors are extensively screened to rule out systemic illnesses, 
other donor-related variables, such as age, may be important. MSCs from aging 
(murine) donors demonstrated reduced efficacy [107]. Variations in production 
and cryopreservation methods may impact variability in the function of MSCs 
when tested in preclinical models or in patients for specific clinical disorders. 
Dimethyl sulfoxide and cell debris are removed by centrifugation after the cryopre-
served MSCs have been thawed and cells are suspended in plasmalyte before intra-
venous administration in preclinical studies of lung injury. Current clinical studies 
are focused on a single dose of MSC administration via the less-invasive intravenous 
route with the START trial demonstrating safety for this approach [108].
6. Conclusions
Extensive progress has been made in the last years concerning cell therapy 
for sepsis and ARDS. Cell therapies have shown promising results in pre-clinical 
Innovations in Cell Research and Therapy
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studies. Several pathways, proteins, miRNAs, and lipids have been characterized 
and explain the mechanism of action of these cell therapies.
Several questions need further study, including determining the best source for 
the MSCs isolation, their large-scale production, and cryopreservation. Moreover, 
the therapeutic potential of MSCs and its conditioned media need to be studied for 
checking their efficacy in short-term and long-term follow-up studies.
The heterogeneity of patients with sepsis and ARDS is enormous, and establish a 
target population or the stratification of the patients will help us to determine better 
the therapeutic effect of these therapies.
There are many complications and concerns with using stem cells for cell-based 
therapy. The future may emphasis on the stimulation of other cells (growth factors, 
cytokines, and various other hematopoietic elements) that facilitate the formation 
or repair of endothelium and epithelium and the modulation of inflammatory cells.
We need to await evidence that these cell therapies have a benefit in patients 
with sepsis or ARDS and evaluate the phase I and II results from the ongoing 
studies.
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